Skip to content

Immunogenicity of Fractional Dose of the HPV Vaccines

Ongoing study. No longer enrolling new participants.

The University of Washington is seeking volunteers for an open-label, randomized trial of a fractional dose of the HPV vaccine. The purpose of this research study is to determine if a fractional dose of the HPV vaccine produces a detectable immune response.

Participants will be assigned by chance (like flipping a coin) to either Gardasil (HPV-9) or Cervarix (HPV-2) FDA-approved vaccine. Participants will know which vaccine they are assigned to. Participants receive a fractional, one-fifth dose of the vaccine at the first visit. The study will last for one year and involve 4 visits. All visits will include blood draws.

To be eligible for the study you must:

  • Be between the ages of 27-45
  • Be in good health
  • Have a flexible schedule to allow for vaccination on specific days determined by the clinic

Conditions which would prevent you from participating in this study:

  • Have previously received the HPV vaccine
  • Have any known impairment of the immune system
  • Have HIV infection
  • Pregnant or breast-feeding

Compensation:

You will be compensated for time and travel during the study.

Clinic Location:

Our clinic is located on the 11th floor of the Ninth and Jefferson Building at Harborview Medical Center and open Monday through Friday.

If you are interested in participating in this study, please fill out this form so the study staff can contact you. If you would like to contact us yourself, you can call us at (206) 520-4340 or email us.

Skip to toolbar